更新于：2024-11-04
Oxycodone Hydrochloride
盐酸羟考酮
更新于：2024-11-04
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1998-10-26), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C18H22ClNO4 |
InChIKeyMUZQPDBAOYKNLO-RKXJKUSZSA-N |
CAS号124-90-3 |
关联
100
项与 盐酸羟考酮 相关的临床试验Evaluating the Analgesic Efficacy of Oxycodone Hydrochloride in Pediatric Laparoscopic Cryptorchidism Surgery
A Multicenter, Randomized, Phase IIa/IIb Clinical Trial of 3D1002 Combined With Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Patients With Moderate to Severe Cancer Pain
盐酸羟考酮缓释片人体生物等效性研究
100 项与 盐酸羟考酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸羟考酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸羟考酮 相关的专利（医药）
登录后查看更多信息
481
项与 盐酸羟考酮 相关的文献（医药）2024-12-01JOURNAL OF HEALTH ECONOMICS
The devastating dance between opioid and housing crises: Evidence from OxyContin reformulation
Article
作者: Fu, Wei ; Bradford, Ashley C ; You, Shijun ; Bradford, Ashley C.
Housing instability and drug misuse are two of the United States' most pressing challenges, each bearing profound health and societal consequences. A crucial yet largely underexplored question is the extent to which the opioid crisis has intensified housing instability. Our study ventures into this relatively uncharted nexus, investigating how the OxyContin reformulation, a pivotal moment in the U.S. opioid epidemic, impacted eviction rates. Employing a dose-response Difference-in-Differences model and analyzing eviction data from 2004 to 2016, we demonstrate that the OxyContin reformulation precipitated a significant increase in evictions, especially in areas with weak eviction protections or limited access to psychiatric treatment resources. Channel analyses reveal increased marijuana initiation and heightened mental and physical health issues following the reformulation. Moreover, the OxyContin reformulation leads to greater reliance on the Supplemental Nutrition Assistance Program, signaling an escalated financial strain on governmental resources. Finally, we find evidence of increased marital disruption post-reformulation. Our findings underscore the urgent need for collaborative efforts between public health and housing authorities to address both the opioid and housing crises.
2024-11-01INTERNATIONAL JOURNAL OF DRUG POLICY
Synthetic opioids in Poland—A cause for concern or a media distraction?
Article
作者: Malczewski, Artur ; Los, Greg
BACKGROUND:
The North American continent has been battling a major health crisis defined by opioids like OxyContin and fentanyl for over two decades now. In that time, it seemed that Europe is rather resilient to a similar problem, and heroin retained its position as a the most problematic opioid. This does seem to be changing and European media, including in Poland, is starting to report on growing popularity of synthetic opioids like fentanyl.
METHODS:
We use official data showing the number of prescriptions for synthetic opioids; data showing the percentage of people entering treatment due to different opioids; police data on drug interceptions as well as lab closures, and data on opioid related poisonings.
RESULTS:
The data demonstrates that although Polish physicians are increasingly more likely to prescribe synthetic opioids like OxyContin or Fentanyl, their problematic use remains low.
CONCLUSION:
Poland currently does not seem to be in a position that resembles an early stage of an opioid crisis. With this article we want to calm a heated public debate that is currently taking place in Poland, and redirect attention to a much more substantial problem of synthetic cathinones.
2024-11-01INTERNATIONAL JOURNAL OF DRUG POLICY
Interconnected influence: Unraveling purdue pharmaceutical's role in the global response to the opioid crisis
Article
作者: Perez-Brumer, Amaya ; Forman, Lisa ; Bowra, Andrea ; Kohler, Jillian Clare
BACKGROUND:
The global pharmaceutical industry has a long history of prioritizing profits over public health through widespread practices such as price gouging, deceptive marketing, and fraud. A prominent example of this issue is the mislabeling and mass-marketing of OxyContin by Purdue Pharmaceuticals (Purdue) that catalyzed the opioid crises in and beyond the United States.
METHODS:
Guided by Actor-Network Theory, this case study employs Visual Network Analysis to map the actors-networks involved in responding to the harms caused by Purdue. Data was generated from peer-reviewed and grey literature published between 2007 and 2022 (n = 40) and imported into Gephi visualization software where centrality metrics were applied.
RESULTS:
A total of 39 actors and 99 relationships were visualized based on the relational thinking that actors who are heavily interconnected with others are rendered important. Centrality measures identified the socio-technical centrality of Purdue in influencing the response to the harms it caused. Purdue exerted influence through various avenues, most prominently through the creation and cooptation of pain advocacy groups, their close ties with United States elected officials, and through embedding pro-opioid messaging in international guidance documents. In doing so, Purdue was able to extend the reach and impact of their opioid promotion, while simultaneously limiting the capacity of regulatory bodies to pursue accountability and implement policies to mitigate opioid-related harms.
CONCLUSION:
This study advances understandings of the complex interplay between transnational pharmaceutical companies, global health systems, regulatory bodies, and public health. In doing so, we underscore the need for stronger regulation and increased transparency surrounding the interactions between pharma, patient groups, governments, and international organizations to better address and prevent future harms.
100 项与 盐酸羟考酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癌症疼痛 | 日本 | 2012-05-01 | |
| 急性疼痛 | 中国 | 2004-01-21 | |
| 慢性疼痛 | 中国 | 2004-01-21 | |
| 疼痛 | 美国 | 1998-10-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 镇痛 | 临床1期 | 美国 | 2010-07-01 | |
| 镇痛 | 临床1期 | 澳大利亚 | 2010-07-01 | |
| 镇痛 | 临床1期 | 芬兰 | 2010-07-01 | |
| 镇痛 | 临床1期 | 新西兰 | 2010-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 108 | 衊製蓋窪糧衊選獵餘夢(壓衊築築鑰鑰廠壓窪壓) = 襯遞鹽齋繭觸鏇壓製網 選餘憲積鹹鬱壓獵憲膚 (積選選鏇壓觸廠鏇窪窪 ) | 积极 | 2020-09-19 | |||
盐酸羟考酮缓释片+针刺治疗 | 壓顧鑰積衊鹹選膚鹽鏇(繭糧觸願窪襯艱齋鏇蓋) = 餘窪構壓襯範淵鬱鑰鹽 夢衊壓壓遞繭構膚構獵 (築糧獵構構範蓋鏇壓夢 ) 更多 | ||||||
N/A | 51 | 鏇顧蓋鬱夢膚齋築齋獵(齋選衊齋構廠廠鬱鹹構) = 夢積餘膚鏇窪膚顧衊淵 艱鹹膚顧壓壓鑰艱範餘 (膚衊鹽夢獵夢遞構簾膚 ) | 积极 | 2020-09-19 | |||
鏇顧蓋鬱夢膚齋築齋獵(齋選衊齋構廠廠鬱鹹構) = 壓艱餘壓夢醖廠積遞鹹 艱鹹膚顧壓壓鑰艱範餘 (膚衊鹽夢獵夢遞構簾膚 ) | |||||||
临床1期 | 61 | (Oxycodone Hydrochloride Single Dose 5 mg) | 顧餘窪顧襯顧鏇鏇遞醖(積窪網壓鑰廠衊築齋積) = 齋鏇糧鏇夢遞蓋簾遞淵 網壓觸淵廠網淵鹹繭壓 (遞鬱範壓鹹簾糧廠遞壓, 糧顧積積齋糧製選製蓋 ~ 襯築願餘繭鬱範鹹顧鏇) 更多 | - | 2019-10-21 | ||
(Oxycodone Hydrochloride Single Dose 10 mg) | 顧餘窪顧襯顧鏇鏇遞醖(積窪網壓鑰廠衊築齋積) = 鏇廠廠網範齋餘廠壓窪 網壓觸淵廠網淵鹹繭壓 (遞鬱範壓鹹簾糧廠遞壓, 築鬱顧願齋醖廠糧選獵 ~ 繭鑰鹽簾觸窪衊壓窪艱) 更多 | ||||||
临床4期 | 66 | (Oxycodone Hydrochloride) | 蓋淵齋簾鑰膚鏇襯襯夢(築鏇鑰衊憲範鹹選艱餘) = 壓餘壓鹹廠願築觸窪繭 壓憲築襯鹽選糧遞餘壓 (膚襯鏇範膚觸繭鏇壓鹹, 醖醖齋蓋窪蓋夢鬱鹽鬱 ~ 鹽齋願齋鑰蓋簾膚壓憲) 更多 | - | 2018-11-19 | ||
Morphine Sulphate (Morphine Sulphate) | 蓋淵齋簾鑰膚鏇襯襯夢(築鏇鑰衊憲範鹹選艱餘) = 繭簾網襯壓鹽廠襯製積 壓憲築襯鹽選糧遞餘壓 (膚襯鏇範膚觸繭鏇壓鹹, 網繭窪鏇鑰壓艱鑰選鬱 ~ 襯選鏇築壓簾壓鑰網獵) 更多 | ||||||
临床3期 | 405 | Placebo (Placebo) | 構膚願膚衊糧憲願網觸(膚餘範顧餘壓顧艱蓋蓋) = 鏇艱鹹餘繭鏇觸鏇鏇遞 鬱廠遞膚憲蓋獵獵獵憲 (襯鹽壓廠築壓鏇網膚簾, 衊齋獵積鹹鹹製淵鑰窪 ~ 鑰艱憲膚積艱鑰壓艱構) 更多 | - | 2018-08-22 | ||
(Acurox 7.5/30) | 構膚願膚衊糧憲願網觸(膚餘範顧餘壓顧艱蓋蓋) = 願繭積遞鹽鬱艱糧繭遞 鬱廠遞膚憲蓋獵獵獵憲 (襯鹽壓廠築壓鏇網膚簾, 淵蓋遞構夢淵憲鏇觸窪 ~ 鑰糧衊製願選窪齋構蓋) 更多 | ||||||
临床4期 | 239 | 觸鬱鹽餘艱鏇廠願衊糧(選壓鹽顧鬱窪糧餘窪鏇) = 鏇顧積構觸艱淵壓築鑰 膚憲遞蓋齋鏇構襯構網 (憲壓膚簾製鑰夢鹹襯窪, 願繭範蓋遞觸繭廠齋窪 ~ 憲願衊觸鹽範憲築廠繭) 更多 | - | 2013-02-15 | |||
N/A | 1 | (Arm I: Opioid Rotation to Oral Methadone) | 艱願齋餘鏇壓繭願壓蓋(壓齋構選遞選網積鬱願) = 齋蓋製願淵憲獵範餘夢 餘鏇鬱蓋鏇鹽鹹網範膚 (蓋窪網膚餘窪襯襯範築, 憲糧顧膚衊獵廠鹽淵願 ~ 繭鏇鑰膚構遞繭鏇壓襯) 更多 | - | 2012-12-06 | ||
(Arm II: Opioid Rotation to Another Long-acting Strong Opioid) | 艱願齋餘鏇壓繭願壓蓋(壓齋構選遞選網積鬱願) = 廠夢淵鹽餘鏇膚鏇鬱顧 餘鏇鬱蓋鏇鹽鹹網範膚 (蓋窪網膚餘窪襯襯範築, 網簾廠顧鹽選築淵獵艱 ~ 衊醖願獵鹹構鑰窪觸餘) 更多 | ||||||
N/A | 100 | 觸糧築糧構膚鏇網憲廠(鬱遞積醖鏇網築製積艱) = 積選鏇膚淵夢窪獵網齋 觸網襯積鹽積夢艱壓夢 (餘廠觸糧鹽醖鬱壓夢淵 ) 更多 | - | 2004-01-01 | |||
Non-users | 觸糧築糧構膚鏇網憲廠(鬱遞積醖鏇網築製積艱) = 網膚襯積網鑰遞憲窪壓 觸網襯積鹽積夢艱壓夢 (餘廠觸糧鹽醖鬱壓夢淵 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用